Clusterin from human clinical tear samples: Positive correlation between tear concentration and Schirmer strip test results
and/or increased tear evaporation causes tear hyperosmolarity and desiccating stress, which stimulates inflammation and expression/activity of matrix metalloproteinases (MMPs). This can lead to ocular surface disease characterized by increased apoptosis, desquamation and barrier disruption, which is visualized as punctate staining with clinical dyes [3] .
Clusterin (CLU 2 ) is a secreted glycoprotein that serves as a "molecular chaperone". As such it is part of an extracellular quality control system maintaining proteostasis by binding to misfolded proteins, inhibiting their precipitation and participating in their clearance from bodily fluids as high molecular weight soluble complexes [4] [5] [6] . Experimental immunodepletion of CLU from human blood renders other plasma proteins susceptible to stress-induced precipitation [7] . CLU is found in insoluble protein deposits in diseases of amyloid deposition such as pseudoexfoliation glaucoma and Alzheimer's disease, perhaps representing an aborted attempt to fulfill the molecular chaperone role [8] . However, studies show that if CLU attains a critical concentration threshold, it potently inhibits deposit formation and provides substantial cytoprotection [8] . CLU is also proteostatic by virtue of its ability to serve as a potent inhibitor of several MMP family proteinases [9, 10] . An early study characterizing CLU revealed a striking level of expression in mucosal epithelial cells, as well as several non-epithelial secretory cell types from a broad range of tissues that form cellular interfaces with fluid compartments [11] . The results suggested that localized CLU synthesis might be particularly important for protection of fluid barrier tissues. CLU protein is found in the apical cell layers of the ocular surface epithelia [12] [13] [14] and mass spectrometric analyses have consistently identified CLU in human tears (e.g., [15] [16] [17] [18] [19] [20] [21] ). CLU in the ocular surface epithelia decreases dramatically in inflammatory disorders that manifest as severe dry eye [22] [23] [24] . Using a mouse model for desiccating stress that mimics human dry eye, we recently provided the first causal evidence in support of the idea that tear CLU protects the ocular surface. We showed that CLU prevent and ameliorates ocular surface signs of dry eye when present in sufficient amounts in the tears [25] , either endogenously, or when supplemented by topical application. Tear CLU concentration was reduced to about 2/3rds of normal in mice subjected to desiccating stress, dropping below the critical threshold. This suggested that there is an optimal concentration of tear CLU needed for ocular surface health, and that this concentration might drop below the effective threshold in dry eye. If so, supplementation could be therapeutic.
In this report, we describe the results of two independent but coordinated studies conducted with the common goal to determine for the first time, the concentration and biochemical characteristics of CLU in human tears, and to investigate whether changes in these parameters are correlated with clinical signs and symptoms of dry eye.
Methods

Ethics statement and human subjects
The two studies described herein were compliant with the Declaration of Helsinki, the Health Insurance Portability and Accountability Act (HIPAA), and the Institutional Review Boards of the University of Arizona Tucson and the University of Southern California (USC; Los Angeles). Informed consent was obtained from all research subjects after explanation of the nature of the study and possible consequences.
In the first study, patients were recruited in Tucson as part of a larger investigation ongoing at the University of Arizona headed by Dr. Mingwu Wang. Patients were enrolled into the study in Dr. Wang's cornea clinic under the parent protocol, and all patient data and specimens were collected at this site. After results were obtained from the Tucson study, a second study was conducted in Los Angeles with the goal to independently corroborate results of the first. Patients were enrolled from the cornea clinic at the USC Roski Eye Institute on the USC Health Sciences Campus under Drs. Martin Heur and Charles Flowers.
Study design
We utilized a cohort study design to enroll subjects across the spectrum of dry eye signs and symptoms. Subjects over 18 years of age were enrolled as they came into the eye care clinic for a scheduled appointment. Subjects were enrolled without regard to sex, gender, race or ethnic origin. Children were not included, since dry eye is a disease of aging. Chart records of inflammatory or autoimmune disorders of the ocular surface were recorded for each enrolled subject.
To assess dry eye signs in enrolled subjects, several standard clinical tests were used (procedures described below). Tests were performed for both the left and right eyes separately. All test variables are presented as the mean ± SD. To assess dry eye symptoms, all enrolled subjects were asked to fill out the Ocular Surface Disease Index, a set of 12 multiple choice questions [26, 27] .
Tears were collected on Schirmer test strips from both the left and right eyes separately, and CLU was extracted for analysis (method described below). As discussed more in the next sections, these samples allowed us to obtain a relative measure of CLU concentration. To directly measure the actual CLU concentration, tear samples were also collected in Tucson by micropipette, if possible, from both the left and right eyes separately (discussed more below).
We estimated sample size for our study using data from mouse experiments and from the Tucson clinic. In the published mouse study, CLU tear concentration was reduced by ∼30% in mice subjected to desiccating stress [25] . Prior Tucson clinic data for fluorescein staining on the standard clinical scale of 1-15 was as follows: mean = 6; standard deviation (SD) = 3. Assuming a 30% reduction in means relative to healthy subjects, this translates to an effect size of 0.6 ((6-4.2)/3). Thus, to detect a reasonable group mean difference in CLU, testing at a 2-sided alpha = 0.05, with 80% power, and incorporating a 0.5 correlation between eyes (within subject), 34 subjects (68 eyes) per group would be required. This sample size would also provide 80% power to detect within-group correlations of 0.40 and higher with 34 subjects (68 eyes), and 0.29 and higher in a combined sample of 68 (128) subjects (eyes).
Clinical tests for dry eye signs
In the Tucson study, four clinical tests were used to assess signs of dry eye. Three are tests of tear dysfunction: 1) Schirmer strip test, 2) tear break-up time and 3) tear osmolarity. The fourth test was fluorescein staining, which assesses ocular surface damage.
The Schirmer strip test uses calibrated filter paper strips to measure tear flow [28] . Test strips were purchased from Alcon Laboratories, Inc. (Fort Worth, TX). To administer the test, the "head" portion of the strip was placed with gloved hands over the subject's lid margin, at the junction of the lateral and middle thirds of the lower eyelids, and the eyes were closed for 5 min. The strip was then removed and the progress of fluid flow onto the body of the strip by passive capillary action was recorded from the calibration markings. The test was performed without anesthetic according to the parent protocol, the rationale being to avoid any possible dilution of the tears with the anesthetic. (Dilution was a concern of the investigators at the Tucson site since concentration measurements were planned; whether tear dilution actually occurred was not specifically investigated.)
Tear break-up time is a measure of tear quality and vulnerability to evaporation [3] . Briefly, fluorescein was instilled onto the ocular surface and the patient was asked not to blink while the tear film was observed under a broad beam of cobalt blue illumination. The tear break-up time was recorded as the number of seconds that elapsed between the last blink and the appearance of the first dry spot in the tear film. Tear osmolarity, a measure of salt concentration (due to reduced tear aqueous volume), utilized the TearLab device [29, 30] .
Fluorescein staining was quantified using the standard National Eye Institute grading system [31] . Briefly, the cornea is divided into 5 areas (central, superior, nasal, inferior and temporal); punctate fluorescein staining in each area is graded on a scale of 0-3, with 3 being the most severe. The scores from all five areas are then summed, for a final score of 0-15.
In the Los Angeles study (informed by experience obtained with the Tucson study), a more streamlined set of tests for dry eye signs was used: 1) the Schirmer strip test and 2) corneal grading for ocular surface damage assessment. Some minor modifications were made in the Schirmer strip test to fit the practices of the Los Angeles clinic. First, the clinic purchased Schirmer strips from a local supplier (HUB Pharmaceuticals, LLC, Rancho Cucamonga, CA). In addition, the clinic insisted on use of a local anesthetic for patient comfort (0.5% Proparacaine Hydrochloride). Corneal grading was used instead of fluorescein staining, also because this was the practice of the Los Angeles clinic. Briefly, this involved careful inspection of the ocular surface for punctate epithelial erosions without the use of stain. Eyes were graded on a scale of 0-5, with 5 being the most severe.
Tear sample collection procedures
Following the Schirmer strip test, which was performed on all subjects enrolled in both the Tucson and Los Angeles clinics, tear-saturated test strips from each eye of a given subject were saved for extraction and analysis of collected tear proteins by placing them individually into sterile 2-mL centrifuge tubes.
Efforts were made at the Tucson site to also collect tear samples on all participants by micropipette. This was done at the slit lamp from each eye, using a fine 5 μL pipette tip point, precisely at the tear lake at the medial canthal area. In this way, the ocular surface tissues were not touched or stimulated. Each time, based on the accumulation at this location, 1 or 2 μL of tears were aspirated from each eye. Some eyes had an inadequate tear lake for aspiration and hence failed to generate any tear samples. In general, if it were possible to collect a sample from one eye of a given individual, it was also possible to collect a sample from the other eye. However, in some cases, we could obtain samples from only a single eye of a specific individual. Samples from each eye were placed in separate 2-mL centrifuge tubes and diluted with PBS to increase stability.
All sample tubes were set on dry ice, then stored at −80°C until they were sent on dry ice to the Fini research laboratory at USC. Samples were stored at −80°C until analysis.
Extraction of proteins from Schirmer strips
The measurement of tear volume using the calibration on the Schirmer test strip is a relative (not an absolute) measurement of tear volume, meaning it was not possible to calculate the actual concentration of CLU. Thus, we chose to compare the amount of CLU collected from equal volumes of tears by extracting only the "head" of each strip, each head being equal in size and completely saturated by tears in all cases. Extraction was performed according to a method previously described [32] . Briefly, the head was removed from the strip and placed in a new 2-mL centrifuge tube containing 100 μL of elution buffer (100 mM ammonium bicarbonate, 0.25% NP-40) with addition of proteinase inhibitors cocktail (Roche, Indianapolis, IN). Proteins were eluted by incubating the tubes on a rotator overnight at 4°C, followed by micro-centrifugation (10,000 rpm, 5 min). Protein was precipitated in acetone, then dissolved in diluent buffer provided with the Human Clusterin Quantikine ELISA kit (R&D Systems, Minneapolis, MN).
CLU quantification
CLU was quantified for each sample (protein solution eluted from a Schirmer strip head or a sample collected by micropipette) individually by enzyme-linked immunosorbent assay (ELISA) using the Human Clusterin Quantikine ELISA kit (R&D Systems). To prepare samples for analysis, 50 μL (half) of the protein solution eluted from each Schirmer strip head, or 0.5 μL of each micropipette-collected sample, was supplemented with assay diluent to 100 μL, as specified by the manufacturer. Raw ELISA quantification results were compared to a CLU standard curve, newly constructed each time a set of samples was analyzed. The resulting values were described in ng/strip head (Schirmer strip) or ug/mL (micropipette). The former is a comparative concentration measure; the latter is an actual concentration measure.
Correlation analysis
De-identified data were analyzed by statisticians from the Southern California Clinical and Translational Science Institute (SC-CTSI) to determine the association between tear CLU concentration and clinical test scores. Measurements from the two eyes of a single subject are often positively correlated, resembling each other more than they do measurements from the eyes of other subjects. This inter-eye correlation must be accounted for in analysis [33] . Thus, the Pearson correlation coefficient, r, was used to assess the degree of linear association between the independent variable, CLU amount per strip head, and the dependent variable, the clinical test score (clinical outcome), for the right eye and left eye respectively. Then, linear regression with a random effect model (specifying a random effect for subject) was used to assess the CLU versus clinical test correlation for both eyes, accounting for repeated measurement from the same individual (i.e., both left and right eyes from the same participant). All significance tests were two-sided, and statistical significance was set at P < 0.05. Data were analyzed using SPSS for Windows (Version 12.0, SPSS Inc., Chicago, IL).
Western blotting
Proteins in Schirmer strip extracts and tear samples were separated by SDS-PAGE and transferred to plastic membranes. Membranes were probed with primary antibody against CLU and developed by chemiluminescence with Luminol enhancer solution and peroxide solution (GE Healthcare UK limited, Buckinghamshire, UK). Images were captured with a Fujifilm imaging system (LAS-4000; Fujifilm, Tokyo, Japan).
CLU from clinical samples was compared with CLU derived from two different non-clinical sources. Natural secreted human serum CLU was purified in the Wilson lab from discarded human blood according to an immunoaffinity protocol previously described [34] . In addition, non-clinical tears were collected from a male subject enrolled in the USC research laboratory; this individual did not report any dry eye symptoms. A published tear wash method was utilized to collect this sample [35] . Briefly, both eyes were washed 6 times (1 drop/time) with Refresh (Allergan, Irvine, CA) and a total of 110 μL was collected from the inferior fornix by micropipette and transferred into a sterile polypropylene tube.
Two different CLU antibodies were used to probe the western blots. One was a rabbit polyclonal antibody (Catalog no. Ab69644, from Abcam, Cambridge, MA) raised against a synthetic peptide matching a sequence near the C-terminus of the human CLU beta-chain. The second antibody was a goat polyclonal antibody raised against mouse CLU
The Ocular Surface 16 (2018) [478] [479] [480] [481] [482] [483] [484] [485] [486] (catalog no. sc-6420, from Santa Cruz Biotech, Dallas, Texas), recommended for detection of mouse, rat and human CLU (Santa Cruz Biotechnology, Dallas, TX). The epitope recognized by the antibody maps at the C-terminus of the CLU alpha-chain. (See Fig. 2A for a graphic of CLU structure showing the two protein chains).
Results
Characteristics and clinical test scores of study subjects
Characteristics and clinical test scores of the subjects from the two different studies are compiled in Table 1. A total of 44 subjects were enrolled in the Tucson cohort. One laboratory worker quantified CLU collected on individual Schirmer test strips for the first 16 patients enrolled (group A), while a second laboratory worker performed this task for samples from the rest of the patients (group B). Subjects for which it was possible to also obtain tear samples were a subset of the second set of patients (subgroup B1).
A total of 52 subjects were enrolled in the Los Angeles cohort. This time, only a single laboratory worker quantified CLU collected on the individual Schirmer test strips, with determinations for all samples done at the same time. Thus, there was no need to split the cohort into groups.
Tear CLU concentration and clinical test outcome correlation
The mean CLU protein amount extracted from individual Schirmer strip heads for both the Tucson cohort and the Los Angeles cohort is compiled in Table 2 . The results for Tucson group A and group B were systematically different (partially because of use of two different standard curves) and it was realized that they could not be pooled. This was the reason for maintaining the two groups as separate.
Tucson group A was too small (n = 16) for a valid statistical analysis, thus analyses were performed using data from group B only, which was close in size (n = 28) to our power estimate. The compiled data for corneal grading was quite discontinuous, which we attribute to the short scoring range of this test; thus statistical analysis was not performed. Correlation of the CLU amount per strip head to questionnaire test results was not significant.
An example of the Pearson correlation analysis scatter chart results is shown in Fig. 1 . Results for the linear regression analysis of both the Tucson and Los Angeles studies are compiled in Table 3 .
These results, corroborated in two independent studies, indicate that CLU concentration is positively correlated with tear flow, so that a decrease in CLU concentration indicates a decrease in tear flow, a clinical outcome that is a sign of dry eye disease.
Actual concentration of tear CLU
The actual volume of tear samples collected by micropipette from Tucson group B1 patients was measured, making it possible to determine the actual CLU tear concentration. Table 4 summarizes the ELISA data. The mean ± SD CLU concentration was 31 ± 14 μg/mL n/a n/a n/a 0. Autoimmune diagnoses included Sjögren's syndrome, rheumatoid arthritis, lupus erythematosus, psoriatic arthritis, and non-specified autoimmune disease.
The following test scores for dry eye signs are considered as "normal": Schirmer test > 15 mm (with or without anesthetic), tear break-up time > 10 s, tear osmolarity of < 296 mOsm/L, fluorescein staining score < 2, corneal grade = 0. Higher scores on the questionnaire represent greater disability. (n = 18 subjects; 33 eyes; range = 7-48 μg/mL; in one subject, tear collection was possible from only one eye).
Tear sample collection method correlation
The fact that tear samples were collected by both Schirmer test strip and micropipette for subgroup B1 of the Tucson B cohort provided an opportunity to compare the two methods to determine their equivalence. The correlation for the right eye was not significant (r = 0.33, slope = 0.17, p = 0.192); however the correlation for the left eye was significant (r = 0.62, slope = 0.31, p = 0.013). There was also a significant correlation between CLU amount collected by the two methods analyzing across both eyes with adjustment for repeated measures as shown in Table 5 (slope estimate = 0.18, 95% CI = 0.02-0.35, p = 0.032).
These results indicate that measurement of tear CLU concentration by the two tear collection methods correlate with one another.
Biochemical Characterization of Tear CLU
Western blot analysis was performed on tear samples to assess biochemical characteristics of tear CLU. Representative results are shown in Fig. 2 . First, a schematic of CLU structure is provided as an aid A) The scatter graph illustrates the range of data distribution for the left eye.
The correlation is statistically significant (R = 0.362, p = 0.008). B) The scatter graph illustrates the range of data distribution for the right eye.
The correlation is not statistically significant (R = 0.172, p = 0.224).
Fig. 2. Biochemical characterization of tear CLU.
A) Predicted structure of secreted human CLU (adapted from Refs. [6, 76, 77] ). Secreted CLU exhibits an apparent mass of 75-80 kDa by SDS-PAGE, although the actual mass is ∼58-63 kDa. It is composed of two polypeptide chains derived from an intracellular precursor. In the first processing step, the 22-mer secretory signal peptide is cleaved from the 449-amino acid precursor. Subsequently the chain is cleaved again between Arg227-Ser228 to generate an alpha-chain and beta-chain of approximately equal length. These are assembled in anti-parallel fashion and linked at the cysteine-rich center by five disulfide bridges (black lines) to generate a heterodimeric molecule with four "arms". Amphipathic alpha-helices (yellow ovals) located near the ends of each of the otherwise disordered arms are thought important for binding to hydrophobic regions exposed on denatured proteins and for insertion into lipid structures. Sites for N-linked glycosylation (white spots) are located around the cysteinerich center of each chain resulting in a molecule that is 17-27% carbohydrate by weight. Amino acid numbering for the N-and C-termini, the cleavage sites, and the sites for N-linked glycosylation are indicated, as in Ref. [78] . Schematic originally published in Ref. [36] , used with permission. B to E) Western blots of purified human blood serum CLU and human tear CLU samples probed with CLU antibodies are shown. The blots in panels B, D, E were probed with a polyclonal antibody raised against a synthetic peptide matching a sequence near the C-terminus of the CLU beta-chain (see schematic, panel A). The blot in panel C was probed with a polyclonal antibody that recognizes an epitope mapping to the C-terminus of the CLU alpha-chain (see schematic, panel A; more details on the antibodies in the Methods section). Beta-MeOH = beta-mercaptoethanol. R = right eye, L = left eye; CLU amounts loaded on gels were determined by ELISA; The electrophoretic position of molecular size standards (in kDa) is indicated. 
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The Ocular Surface 16 (2018) [478] [479] [480] [481] [482] [483] [484] [485] [486] to understanding the analysis and results ( Fig. 2A) . CLU derived from the tears of a non-clinical subject exhibited an apparent size of ∼75 kDa (Fig. 2B) , the apparent size typical for CLU obtained from various bodily fluids [36] . When the sample was reduced by addition of beta-mercaptoethanol to break the disulfide bonds in the CLU molecule, tear CLU appeared as a single band migrating at about 37 kDa, consistent with dissociation into two polypeptide chains of approximately equal size (only one of which was recognized by the antibody used to probe the western blot) (Fig. 2B ). This electrophoretic behavior was indistinguishable from human serum CLU (Fig. 2C) . The small amount of CLU that did not dissociate into two polypeptide chains after treatment with beta-mercaptoethanol is typically observed, and represents unprocessed protein. CLU from one of the two micropipette-collected samples analyzed from Tucson cohort subgroup B1 appeared to be cleaved at the C-terminus of the beta chain, generating two small fragment of ∼15 kDa that were bound by the CLU antibody (Fig. 2D) . This would remove one of the C-terminal amphipathic helices, raising the intriguing possibility that it is an inactivating cleavage. However, this cleavage was not identified in 8 different tear samples eluted from Schirmer strips collected from the Los Angeles cohort (Fig. 2E , thus, may not be of general significance. In addition, no higher molecular weight aggregates that might represent CLU bound to denatured client proteins were evident in any of the samples. These results indicate that tear CLU is biochemically similar to the form of CLU found in blood, and is not substantially different in the tears of patients with signs and symptoms of dry eye.
Discussion
CLU is an important component of the quality control system in bodily fluids that maintains proteins, also called "proteostasis" [4] [5] [6] . We recently demonstrated, using a mouse model for desiccating stress, that CLU prevents and ameliorates ocular surface signs of dry eye disease if present in sufficient amounts in the tears. However, when CLU tear concentration dips below a critical threshold, the ocular surface became vulnerable [25] . Our results suggested that tear CLU needed for health of the ocular surface might become limiting in human dry eye disease, and that topical supplementation might be therapeutic. The current study investigated whether tear CLU concentration correlates with dry eye signs and symptoms in people. Consistent with our hypothesis, we found that CLU concentration is positively correlated with Schirmer strip test results. Lower CLU concentration indicates a decrease in tear flow, a clinical outcome that is a sign of dry eye disease. This result was corroborated in two independent studies. We further report a tear CLU concentration of 31 ± 14 μg/mL (n = 18 subjects; 33 eyes; range = 7-48 μg/mL), determined by ELISA using tear samples from patients with a broad range of test scores for dry eye signs and symptoms. Finally, we show that tear CLU is biochemically similar to CLU from blood plasma. CLU present in clinical tear samples is also biochemically similar to non-clinical samples, suggesting that the protein in clinical tears is functional, even when concentration is reduced. CLU concentration varies widely in different human bodily fluids. Table 6A summarizes information about this, derived from the scientific literature. The value determined here by ELISA of ∼30 μg/mL for human tear CLU is about 3-fold lower than the most recently reported value of 101 ± 42 μg/mL for human blood serum, also determined by ELISA [37] . CLU has previously been identified in tear proteomics profiles of normal subjects [15, [17] [18] [19] 38] , dry eye subjects [39] , and subjects with pterygium, Sjögren's syndrome and diabetes [16, 40, 41] , however its concentration has never been determined. Table 6B summarizes information taken from the scientific literature that provides context to other tear proteins. A small number of highly abundant proteins are estimated to comprise more than 90% of the total tear protein by weight, including lysozyme (LYZ), lactoferrin (LTF) tear lipocalin (LCN1) and lacritin (LACRT) [42] . However, the remaining 10% is highly complex; in the most comprehensive mass spectrometry list, 1543 tear proteins were identified [17] . At ∼30 μg/mL, CLU abundance is substantially lower than that of the major tear proteins (e.g., ∼50 fold less than LCN1 and ∼10-fold less than LACRT), but near the upper end of abundance for the other proteins. This is consistent with the hypothesis that there is an optimal concentration of tear CLU needed for ocular surface health.
Both reduced and elevated levels of CLU are associated with disease states. The former likely represents dysfunction, and the latter reflects a compensatory stress response, which may or may not be sufficient to bring CLU to the necessary level [43] . While we report reduced CLU concentration associated with reduced tear flow here, elevated CLU in the saliva has been associated with Sjögren's syndrome [44, 45] , a disease that also manifests as dry eye [46] . Low plasma CLU concentration is associated with an adverse prognosis in patients with chronic heart failure independent of traditional cardiovascular risk factors and potential confounders [47] . An increased CLU concentration is associated with severity, pathology, and progression of Alzheimer's disease [48] and cognitive impairment [49] . However, functional analyses suggest reduced secretion of CLU protein as the mode of action for three of the examined CLU mutations associated with Alzheimer's disease [50] . The fact that CLU concentration in cerebrospinal fluid is quite low, suggested that the levels could be easily overwhelmed in disease and prompted the proposal that CLU supplementation might be of therapeutic value in Alzheimer's disease [50] . Our findings here support the idea that supplementation might be of value for dry eye disease as well. The range of tear CLU concentrations measured here of 7-48 μg/mL provides a starting point around which to design a dose range for topical supplementation in clinical trials. An interesting finding of this study was the consistent observation that a reduction in the Schirmer test for tear flow correlated to a reduction in tear CLU concentration for the left eye, but not for the right. Perhaps of relevance is the report that cataracts and skin cancers appear on the left side of the face in North America at a greater frequency than on the right. Since the opposite correlation is observed in countries that drive motor vehicles on the other side of the road, it has been theorized that greater sun exposure through the driver-side window accelerates the correlated pathologies [51] . The ocular surface epithelia can also be damaged by sun exposure [52] , thus perhaps something similar can explain our results. While results in the right eye were not statistically significant in our study, we observed the same correlative trend as in the left eye. We suspect that the right eye data would also become statistically significant in a study with a larger sample size.
Why would CLU concentration be lower in patients with reduced tear flow? To answer this question, it is helpful to consider where CLU is synthesized. CLU mRNA appears in RNA profiles of the human lacrimal glands [55, 56] , meibomian glands [56] and accessory lacrimal glands of Wolfring [57] and CLU protein is localized to CD31-positive endothelial-like cells in the lacrimal gland of mice [58] . Lacrimal gland dysfunction leading to aqueous-deficient dry eye might also cause a reduction in CLU protein secretion, as has been suggested for LCN1 and LACRT [38] .
Shedding and lysis of apical epithelial cells also contribute to the tear protein profile [42] . CLU mRNA is expressed throughout the corneal epithelium, but the protein product is found in humans [12] [13] [14] 59] and mice [10] only in the apical cell layers. When these mucosal epithelial cells undergo squamous metaplasia in dry eye, CLU protein is depleted [60] . This would translate into a lower concentration of CLU in the tears.
There has been much interest in developing a tear protein biomarker profile for dry eye and other ocular surface diseases [38, 42] . Two recent studies compare relative CLU levels in subjects with and without dry eye. The first suggested that the tear CLU concentration was reduced in type 2 diabetic patients with dry eye [41] . The second study suggested that tear CLU could serve as a biomarker for Sjögren's syndrome patients with dry eye [40] . However, in both cases, a very small number of samples were pooled and analyzed as a group, and the analyses were not quantitative. Tear CLU was reported as non-detectable in the normal samples from the second study [40] , which is not consistent with the findings reported here and in other publications [15, [17] [18] [19] 38] . Our current study is the first that is sufficiently powered statistically to achieve a meaningful comparison of tear CLU levels in normal and dry eye subjects. The range of CLU concentrations (as apparent in Table 2 and Fig. 1 ) is typical of biological samples; however, if CLU reduction corresponds only with one type of dry eye (such as aqueous deficient), this would increase variability. Thus, tear CLU concentration could probably not be used to diagnose dry eye (unless it becomes possible to stratify for dry eye subtype), but still might serve as a proxy for assessing efficacy of investigational new drugs in clinical trials powered with sufficient number of subjects for statistical significance. It might also be used to identify patients that could benefit from CLU supplementation therapy.
In this study, samples were collected without topical anesthesia (Tucson cohort) and with topical anesthesia (Los Angeles cohort). The question of topical anesthetic use has been investigated in numerous publications and although tear secretion generally decreases, there are many associated variables [61] . In our study, the mean Schirmer test scores were quite similar (Table 1 ) and in both cases, a significant correlation with CLU concentration was observed. In addition, the correlation between CLU concentration measurement by Schirmer strip sampling without anesthesia, and pipette sampling (Table 5) , which would not stimulate reflex tearing as performed in this study, suggests that anesthesia was not a confounding factor in our results. The use of anesthesia is more comfortable for the patient, providing for a better experience. Sampling of tears by Schirmer test strip is more acceptable to the patient than the pipette method, and has the advantage of being part of a routine clinical work-up.
Why was a significant correlation observed only with the Schirmer test, and not the other tests performed for signs and symptoms of dry eye? The Schirmer strip test measures tear flow, which is reduced in "aqueous-deficient" dry eye, characterized by a reduction in the secretions from the lacrimal glands that produce the aqueous component of the tears [53] . Thus, a reduction in CLU concentration may correspond best with aqueous deficient dry eye. Since no reliable tests exist to diagnose dry eye subtype at this time, this can only be conjecture [3, 54] .
Conclusions
Our previous work in a mouse model for dry eye disease suggested that reduction of tear CLU below a critical threshold results in ocular surface vulnerability to stress [25] . Results reported here support the hypothesis that an optimal concentration of tear CLU is important for ocular surface health, and that this concentration drops below the effective threshold in dry eye. Tear CLU measurement might identify patients that could benefit from supplementation. Information about concentration, reported here for the first time, will be valuable for developing therapeutic dosage parameters. The total protein concentration in human tears was recently estimated at 6-11 mg/mL [70] . A few highly abundant proteins, including lysozyme (LYZ), lactoferrin (LTF) and tear lipocalin (LCN1), comprise 70 to 85% of this total [72] . Expanding to the next level of abundance to include a small group of additional proteins, such as secretory immunoglobin A (IGA), lacritin (LACRT), and proline-rich proteins (PRRL4, PROL1, etc.), increases this value to more than 90% [42] . In the most comprehensive mass spectrometry list, 1543 different tear proteins were identified [17] , and this list includes the remaining 10%. At ∼30 μg/mL, CLU is at the top end. The value of 30 μg/mL is consistent with the ranking of CLU on mass spectrometry protein abundance lists (e.g., [17] ).
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